Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

162 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

InvestigationalRegistered later-phase trial

Cancer type: Leukemia
Trial identifier: NCT07297914
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants ages 3 Months to 25 Years with Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07297914 (opens in a new tab) (Clinical-trial registry) NCT07297914 Primary source NCT07297914
ClinicalTrials.gov — NCT07297914. NCT07297914.

Eligibility varies — review trial criteria.

Trial Watch: A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

InvestigationalRegistered later-phase trial

Cancer type: Kidney (Renal) Cancer
Trial identifier: NCT04195750
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Carcinoma, Renal Cell who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT04195750 (opens in a new tab) (Clinical-trial registry) NCT04195750 Primary source NCT04195750
ClinicalTrials.gov — NCT04195750. NCT04195750.

Eligibility varies — review trial criteria.

Trial Watch: Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

InvestigationalRegistered later-phase trial

Cancer type: Endometrial (Uterine) Cancer, Sarcoma
Trial identifier: NCT03914612
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT03914612 (opens in a new tab) (Clinical-trial registry) NCT03914612 Primary source NCT03914612
ClinicalTrials.gov — NCT03914612. NCT03914612.

Eligibility varies — review trial criteria.

Trial Watch: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

InvestigationalRegistered later-phase trial

Cancer type: Prostate Cancer
Trial identifier: NCT06136650
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06136650 (opens in a new tab) (Clinical-trial registry) NCT06136650 Primary source NCT06136650
ClinicalTrials.gov — NCT06136650. NCT06136650.

Eligibility varies — review trial criteria.

Trial Watch: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

InvestigationalRegistered later-phase trial

Cancer type: Sarcoma
Trial identifier: NCT06422806
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06422806 (opens in a new tab) (Clinical-trial registry) NCT06422806 Primary source NCT06422806
ClinicalTrials.gov — NCT06422806. NCT06422806.

Eligibility varies — review trial criteria.

Trial Watch: An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

InvestigationalRegistered later-phase trial

Cancer type: Prostate Cancer
Trial identifier: NCT04076059
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Metastatic Hormone Sensitive Prostate Cancer who meet the study-specific registry eligibility criteria; sex eligibility: male.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT04076059 (opens in a new tab) (Clinical-trial registry) NCT04076059 Primary source NCT04076059
ClinicalTrials.gov — NCT04076059. NCT04076059.

Eligibility varies — review trial criteria.

Trial Watch: DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT07472517
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07472517 (opens in a new tab) (Clinical-trial registry) NCT07472517 Primary source NCT07472517
ClinicalTrials.gov — NCT07472517. NCT07472517.

Eligibility varies — review trial criteria.

Trial Watch: CINC424A2X01B Rollover Protocol

InvestigationalRegistered later-phase trial

Cancer type: Leukemia
Trial identifier: NCT02386800
Trial phase: Phase 4

View trial details

Study design: Not specified in this summary
Population: Participants ages 1 Month to 100 Years with Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT02386800 (opens in a new tab) (Clinical-trial registry) NCT02386800 Primary source NCT02386800
ClinicalTrials.gov — NCT02386800. NCT02386800.

Eligibility varies — review trial criteria.

Trial Watch: Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer

InvestigationalRegistered later-phase trial

Cancer type: Endometrial (Uterine) Cancer
Trial identifier: NCT07860450
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Endometrial Carcinoma, Neoplasms, Endometrial who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07860450 (opens in a new tab) (Clinical-trial registry) NCT07860450 Primary source NCT07860450
ClinicalTrials.gov — NCT07860450. NCT07860450.

Eligibility varies — review trial criteria.

Trial Watch: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT07513376
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Non-small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-20

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-20

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07513376 (opens in a new tab) (Clinical-trial registry) NCT07513376 Primary source NCT07513376
ClinicalTrials.gov — NCT07513376. NCT07513376.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.